Clinical trials: Sitagliptin, completed
Type 1 Diabetes
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.
- Trial name
- NCT01235819
- Testing
- Insulin, Sitagliptin, Exenatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Command Hospital, India
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to compare the efficacy and safety of ASP1941 50mg once daily in combination with metformin and sitagliptin against placebo in combination with metformin and sitagliptin over a 24 week treatment…
- Trial name
- NCT02452632
- Testing
- ASP1941
- Where
- 22 sites in South Korea
- Volunteers
- 143 people
- Sponsor
- Astellas Pharma Korea, Inc.
Diabetes Mellitus, Type 2
Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
The aim of this study is to develop a retrospective, multicenter and observational study in Spain in real clinical practice to assess the employment of dapagliflozin and to compare its effectiveness and safety with the data of…
- Trial name
- NCT04149067
- Testing
- Dapagliflozin, Sitagliptin
- Where
- Spain
- Volunteers
- 1,080 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Type 2 Diabetes
MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
Response to treatment in Type 2 Diabetes is highly variable; the same medicine may have little effect in one person but a large effect in another.
- Trial name
- Mastermind (NCT01847144)
- Testing
- Gliclazide 80mg OD, Sitagliptin 100mg OD
- Where
- United Kingdom
- Volunteers
- 143 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Healthy, Type 2 Diabetes
Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of…
- Trial name
- NCT00885638
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lund University
Type 2 Diabetes
Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing
Main objective : Show that treatment with metformin in patients with type 2 diabetes has an effect on alternative splicing of the insulin receptor.
- Trial name
- METFORGENE (NCT01349387)
- Testing
- Metformin
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Type 2 Diabetes, Overweight
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Trial name
- TIRZSEMA-CVOT (NCT07096063)
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 887,132 people
- Sponsor
- Brigham and Women's Hospital
Polycystic Ovary Syndrome
Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients
The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility
- Trial name
- NCT05972928
- Testing
- Sitagliptin 100mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Beni-Suef University
Psoriasis
Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)
The primary purpose of this study is to determine if sitagliptin (Januvia®) improves psoriasis severity after 24 weeks of treatment in 60 participants with psoriasis who do not have type 2 diabetes mellitus, and who are due to…
- Trial name
- DINUP (NCT02347501)
- Testing
- Sitagliptin (Januvia)
- Where
- Ireland
- Volunteers
- 118 people
- Sponsor
- University College Dublin
Type 1 Diabetic Nephropathy
The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
Diabetic nephropathy (DN) is one of the most frequent microvascular complications of diabetes mellitus, affecting 25 to 40% of patients with type 1 diabetes (T1DM).
- Trial name
- NCT06115460
- Testing
- oral sitagliptin supplementation
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Ain Shams University
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC004 (NCT07763951)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Diabetes After Total Pancreatectomy
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Glucagon is a 29-amino acid peptide hormone of essential importance for glucose homeostasis. Hitherto glucagon has been believed to be secreted only from the pancreas, but recent studies show that glucagon is also secreted from…
- Trial name
- Px-Meal (NCT04061473)
- Testing
- Sitagliptin 100mg, Empagliflozin 25 MG
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
- Trial name
- NCT00337610
- Testing
- sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study.
- Trial name
- DXM2 (NCT01936025)
- Testing
- Dextromethorphan, Sitagliptin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT02683525
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sherif S. Farag
Diabetes Mellitus
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
After 24 weeks of treatment evaluate the efficacy and security.
- Trial name
- NCT00832390
- Testing
- sitagliptin phosphate
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Transplant, Type 2 Diabetes
Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant
This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
- Trial name
- NCT00466518
- Testing
- Administration of sitagliptin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Oklahoma
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Sitagliptin Umbilical Cord Blood Transplant Study
The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).
- Conditions
- Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic
- Trial name
- NCT00862719
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Indiana University